Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

0.73 (USD) • At close January 15, 2025
Bedrijfsnaam Lexicon Pharmaceuticals, Inc.
Symbool LXRX
Munteenheid USD
Prijs 0.728
Beurswaarde 263,021,579
Dividendpercentage 0%
52-weken bereik 0.62 - 3.73
Industrie Biotechnology
Sector Healthcare
CEO Mr. Lonnel Coats
Website https://www.lexpharma.com

An error occurred while fetching data.

Over Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase

Vergelijkbare Aandelen

AlloVir, Inc. logo

AlloVir, Inc.

ALVR

0.381 USD

Dyne Therapeutics, Inc. logo

Dyne Therapeutics, Inc.

DYN

15.54 USD

4D Molecular Therapeutics, Inc. logo

4D Molecular Therapeutics, Inc.

FDMT

5.04 USD

ClearPoint Neuro, Inc. logo

ClearPoint Neuro, Inc.

CLPT

15.115 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)